Isomerization of antimalarial drug WR99210 explains its inactivity in a commercial stock
Rattachement africain : us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
ABSTRACT WR99210, a former antimalarial drug candidate now widely used for the selection of Plasmodium transfectants, selectively targets the parasite dihydrofolate reductase thymidine synthase bifunctional enzyme (DHFR-TS) but not human DHFR, which is not fused with TS. Accordingly, WR99210 and plasmids expressing human dhfr have become valued tools for the genetic modification of parasites in the laboratory. Concerns over the ineffectiveness of WR99210 from some sources encouraged us to investigate the biological and chemical differences of supplies from two different companies (compounds 1 and 2 ). Compound 1 proved effective at low nanomolar concentrations against Plasmodium falciparum parasites, whereas compound 2 was ineffective even at micromolar concentrations. Intact and fragmented mass spectra indicated identical molecular formulae of the unprotonated (free base) structures of 1 and 2 ; however, the compounds displayed differences by thin layer chromatography, reverse phase high performance liquid chromatography, and ultraviolet-visible spectroscopy, indicating important isomeric differences. Structural evaluations by 1 H, 13 C, and 15 N nuclear magnetic resonance spectroscopy confirmed 1 as WR99210 and 2 as an isomeric dihydrotriazine. Induced fit, computational docking models showed that 1 binds tightly and specifically in the P. falciparum DHFR active site whereas 2 fits poorly to the active site in loose and varied orientations. Stocks and concentrates of WR99210 should be monitored for the presence of isomer 2 , particularly when they are not supplied as the hydrochloride salt or are exposed to basic conditions that can promote isomerization. Absorption spectroscopy may serve for assays of the unrearranged and rearranged triazines.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Isomerization of antimalarial drug WR99210 explains its inactivity in a commercial stock
- Date Crossref
- 01/07/2020
- Éditeur
- openRxiv
- Type
- posted-content
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
National Institute of Allergy and Infectious Diseases Office of Cyber Infrastructure and Computational Biology pays non établi dans la noticeStructure de recherche
-
National Institutes of Health pays non établi dans la noticeOrganisme public
-
National Institute of Diabetes and Digestive and Kidney Diseases pays non établi dans la noticeStructure de recherche
-
Otsuka (United States) pays non établi dans la noticeEntreprise
-
Laboratory of Malaria and Vector Research pays non établi dans la noticeStructure de recherche
-
Ntionl Institute of Allergy nd Infectious Diseses Lbortory of Mlri nd Vector Reserch pays non établi dans la noticeStructure de recherche
-
Laboratory of Bioorganic Chemistry pays non établi dans la noticeStructure de recherche
-
National Institute of Diaetes and Digestive and Kidney Diseases Laoratory of Bioorganic Chemistry pays non établi dans la noticeStructure de recherche
-
National Institute of Allergy and Infetious Diseases Offie of Cyber Infrastruture and Computational Biology pays non établi dans la noticeStructure de recherche
-
National Institute of Allergy an Infectious Diseases Research Technologies Branch pays non établi dans la noticeStructure de recherche
-
Jacobus Pharmaceutical Company pays non établi dans la noticeEntreprise
-
Jacobus Pharmacutical Company pays non établi dans la noticeEntreprise
Office of Cyber Infrastructure and Computational Biology — National Institute of Allergy and Infectious Diseases, National Institutes of Health et National Institute of Diabetes and Digestive and Kidney Diseases, avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.